Stay current with the latest press releases, events, and news from IsoPlexis.
IsoPlexis and Yale Partner to Advance COVID-19 Immune Profiling Biomarkers, 2020 Yale University to use IsoPlexis' single-cell immune landscaping & high-plex automated immunoassay solutions to conduct blood-based immune profiling in COVID-19 and identify rapid circulating markers.
IsoPlexis Announces “Single-Cell Proteomics Grant Challenge: COVID-19”, 2020 IsoPlexis, the leader in single-cell proteomics, today announced their Single-Cell Proteomics COVID-19 Grant Challenge, where researchers are invited to share next generation insights using single-cell functional proteomics for the opportunity to win 12 IsoCode or CodePlex chips for a project run on the IsoLight system. Through this grant challenge, researchers can utilize IsoPlexis' unique single-cell proteomics to help resolve the underlying functional mechanisms of COVID-19 to help accelerate the development of novel therapies and vaccines. Applicants should submit an abstract up to 500 words, between August 25, 2020 and September 30, 2020, proposing a project using the IsoLight platform and the Single-Cell Secretome or CodePlex Secretome solutions. A challenge committee will review the proposals and select winners based on research novelty and innovation. Experiments must be completed by November 30, 2020.
IsoPlexis Announces Partnership with Medquest for IsoLight Expansion into Singapore and Malaysia, 2020 IsoPlexis partners with Medquest to expand its single-cell proteomic analysis platform, the IsoLight system and IsoCode & CodePlex Chips, throughout the pharmaceutical and life science markets in Malaysia and Singapore. IsoPlexis' unique single-cell proteomics is helping to speed development of vaccine and antiviral therapies for infectious diseases, including COVID-19. IsoPlexis is currently part of one of the largest COVID-19 consortiums in the US, with patient sample access in Seattle, Washington. Additionally, IsoPlexis has published high impact publications in research areas from cancer immunology, cellular and regenerative medicine, to infectious diseases, oncology, and neuroinflammation. "We are privileged to partner with IsoPlexis in delivering powerful tools in the fight against cancer and advancing future medicine," said Mr. Wan Suhaimi, Managing Director of Medquest.
IsoPlexis and Lonza Collaborate to Enable the Next Generation of Precision Cell Therapy Manufacturing, 2020 IsoPlexis, the leader in single-cell functional proteomics products, today announced a collaboration with Lonza, a leading cell & gene therapy manufacturer, to use IsoPlexis' IsoLight platform. This automated functional proteomics analysis platform will provide quality analytics for cell therapy products generated on Lonza's Cocoon® Platform, an automated, highly flexible cell therapy manufacturing Platform. Lonza's Cocoon® Platform allows for efficient centralized and decentralized manufacturing of novel cell therapies, and IsoPlexis' IsoLight Platform provides a solution for the functional characterization of the cell therapy product, to ensure correlative functional potency of the manufactured cell product. By using the Cocoon® Platform's automated programming and on-board, real-time analytics, the collaboration will seek to significantly improve the biological understanding of starting material, process, and product analytics to enable more efficient manufacturing and higher quality cell therapies.
IsoPlexis Adds Partnership to Advance COVID-19 Vaccine Development, 2020 IsoPlexis, the leader in single-cell functional proteomics, today announced a partnership with the Division of Infectious Diseases, Department of Medicine at Columbia University, IsoPlexis' Single-Cell Secretome immune profiling solutions will be used to study cellular drivers of durable and protective immune response to COVID-19. T cell and other immune cell polyfunctional cytokine responses on IsoPlexis' platform have previously shown to be predictive of a variety of responses in human and mice studies throughout cancer immunology and infectious disease. "We are looking forward to our partnership with Columbia University in the fight against COVID-19," said IsoPlexis Chief Executive Officer, Sean Mackay. "This work will provide critical functional insights into the mechanisms of protective and durable immune response to COVID-19, especially with regards to the activity of T cells."
IsoPlexis Announces Partnership with Neoline Technology Co & IsoLight Expansion into Chinese Life Science Market, 2020 IsoPlexis, the leader in single-cell proteomics products, today announced an exclusive agreement with Neoline Technology Co, a leading distributor for next generation analytical systems, to distribute IsoPlexis' products in China. IsoPlexis' unique single-cell proteomics is helping to speed development of vaccine and antiviral therapies for infectious disease, like COVID-19. IsoPlexis is currently part of one of the largest COVID-19 consortiums in the US, with patient sample access in Seattle, Washington. Additionally, IsoPlexis has published high impact publications in research areas from cancer immunology, cellular and regenerative medicine, to infectious diseases, oncology, and neuroinflammation.
IsoPlexis Strengthens Commercial Leadership with the Appointment of Peter Siesel as Chief Commercial Officer, 2020 IsoPlexis, the leader in single-cell proteomics, today announced that Peter Siesel has joined the company as Chief Commercial Officer. In this role, Mr. Siesel will continue to advance IsoPlexis' commercialization and market expansion efforts by leading global sales and customer support, as well as expansion into key regions for market growth. "We are pleased to have Peter join our executive team at IsoPlexis," said Sean Mackay, co-founder and Chief Executive Officer of IsoPlexis. "Peter has proven leadership and played a critical role in developing and expanding commercial teams in the fast-paced world of the life sciences industry. We are confident that he will bring extensive knowledge to the table and drive further global success in our rapidly growing commercial endeavors."
IsoPlexis Awarded $2 Million NIH Phase 2 SBIR Grant for Expanding Development of a Cellular Platform for Analyzing the Peripheral Immune Response in Alzheimer’s Disease and Neuroinflammation with Single-cell Proteomics, 2020 The funds from this Phase 2 SBIR grant will be used by IsoPlexis to expand the development of a functional proteomic platform to determine effects of the inflammatory immune response on Alzheimer's progression. The IsoPlexis system will allow for the sensitive detection of responses from various immune cells such as peripheral monocytes, highly polyfunctional secretomic T cell types, and microglia, as biomarkers for early stage diagnosis and monitoring of inflammatory neurodegenerative diseases. This unique approach is non-invasive and should have broad impact and unique value for pre-clinical and clinical use.
IsoPlexis Strengthens Executive Leadership Team with Appointment of John Strahley as Chief Financial Officer, 2020 IsoPlexis, the leader in functional cellular proteomics, today announced the appointment of John Strahley as Chief Financial Officer. As CFO, Mr. Strahley will be responsible for the company's strategic planning, finance, accounting, investor relations, and treasury functions, among other pivotal roles. "We look forward to welcoming John to IsoPlexis' executive leadership team," said Sean Mackay, co-founder and Chief Executive Officer of IsoPlexis. "John's deep experience in leading financial institutions as well as his experience with groundbreaking fast paced companies, provides the needed tools to help accelerate our mission."
IsoPlexis and Institute for Systems Biology partner to uncover the functional immune mechanisms behind COVID-19 response, 2020 IsoPlexis, the leader in functional cellular proteomics, and the Institute for Systems Biology (ISB) announced a partnership mapping functional immune responses at the single cell level to study COVID-19. Uncovering functional immune responses using IsoPlexis technologies have underpinned key breakthroughs in therapies that harness the immune system across disease areas. The data from this partnership will be released as soon as possible and made globally available to researchers combatting the disease. Research will be performed on immune cells from individuals who have been diagnosed with or recovered from COVID-19. IsoPlexis' single cell functional proteomics platform will be utilized on a variety of immune cell types, including various T cells and myeloid cells to put together a map of the overall response.
IsoPlexis Launches Suite of New Products Enabling Multiple Automated Applications on the IsoLight, 2020 IsoPlexis, the leader in functional cellular proteomics, today announced the upcoming launch of two new additions to its application family, with the fully automated CodePlex Secretome solution for a faster hands-off approach to obtaining highly multiplexed bulk cytokine data and the Single-Cell Innate & Myeloid solution, which uniquely reveals functional sources of immune suppression from rare subsets of innate and myeloid cells. These new chip applications run on the revolutionary IsoLight system, which serves as a comprehensive automated proteomics hub. The CodePlex Secretome and Single-Cell Innate & Myeloid solution are now available for purchase.
IsoPlexis Closes Additional $20 Million Financing to Continue Commercial Expansion of Single-Cell Systems, 2020 IsoPlexis, the leader in single-cell functional proteomics, has announced today that it has raised an additional $20 million in its Series C financing, bringing the entire Series C round to $45 million. The funding will continue to drive the global commercial expansion of its IsoLight single-cell proteomic analysis platform. The recent financing was led by Northpond Ventures, along with participation from existing investors. In 2020, IsoPlexis will continue to expand its applications and release innovation products addressing high need research areas for its existing and future customer base, including products that address innate & myeloid function, tumor cell signaling, and other high need areas.
IsoPlexis Announces “Cracking the IsoCode: Single Cell Functional Biomarkers Challenge”, 2019 IsoPlexis, the leading single-cell functional proteomics company, has announced their "Cracking the IsoCode: Single Cell Functional Biomarkers Challenge", where researchers are invited to share next generation insights using single-cell functional proteomics for the opportunity to win a project on the IsoLight system at their institution. IsoPlexis is awarding 12 IsoCode chips to two winners whose proposed projects express research novelty and innovation using single-cell functional proteomics.
IsoPlexis Receives $2 Million National Cancer Institute Grant to Target the Functional Pathways in Rare Cancer Cells that Drive Resistance, 2019 IsoPlexis continues to build its pipeline of revolutionary, single-cell, proteomic biology solutions with novel, tumor cell, proteomic signaling pathway technology. IsoPlexis announced today that it has received $2 million in grant funding from the National Cancer Institute's Small Business Innovation Research (NCI SBIR) Development Center for the advancement of intracellular proteomic pathway targeting solutions for single tumor cell analyses.
IsoPlexis’ New Software & Applications Pave the Way for Novel Functional Understanding of Single-Cell Immune Activation and Further Application Expansion, 2019 IsoPlexis, the leader in single-cell functional proteomics, today launched its IsoSpeak Software for automated on-site analysis and advanced, functional, single cell mapping, and two new additions to its application family, with its murine cell solution for pre-clinical immunotherapy profiling and its polyfunctional inflammation solution for profiling a range of inflammatory diseases.
IsoPlexis’ Immune Monitoring Contributions in Precision Medicine Highlighted in Comprehensive Publication, “Biomarkers for Immunotherapy of Cancer”, 2019 IsoPlexis, the leader in single-cell functional proteomics, continues to accelerate immunotherapy development with its IsoLight system, which was highlighted in the recent publication, Biomarkers for Immunotherapy of Cancer. The Springer Protocols book outlines emerging standards for cancer immunotherapy biomarker analysis.
IsoPlexis Continues Progress on Precision CAR-T cell Characterization with Recent Data Sets & Miltenyi Biotec, Inc. Technology Note, 2019 IsoPlexis, the leader in single-cell functional proteomics, continues to build upon recent success in the CAR-T field through NCI funding, advanced cell therapy data sets, and with the release of a co-marketing Tech Note with Miltenyi Biotec, Inc. IsoPlexis & Miltenyi Biotec, Inc. published a technology note showcasing how their respective technologies can be used synergistically to optimize CAR-T bioprocessing workflows. In particular, IsoPlexis' single-cell functional characterization was used to evaluate cell therapy process changes, downstream of Miltenyi Biotec, Inc.'s CliniMACS Prodigy® system.
IsoPlexis Announces Partnership with BioStream & IsoLight Expansion into Japanese Life Science Market, 2019 IsoPlexis, the leader in single-cell functional proteomics products, today announced an exclusive agreement with BioStream Co, a leading distributor for next generation analytical systems, to distribute IsoPlexis' products in Japan. "We are very excited to partner with BioStream, a world class distributor of life science systems and technology in Japan," said IsoPlexis Chief Executive Officer, Sean Mackay. "Our single-cell proteomics platform provides a wide range of applications across development and biomarker discovery in cancer immunotherapy, and we look forward to our systems generating impactful data at leading Japanese pharmaceutical companies, research laboratories, and academic institutions."
IsoPlexis Launches First European Office & Initial IsoLight Single Cell Cytokine Detection System at Karolinska Institute in Sweden, 2019 IsoPlexis, the leading life sciences company in the single-cell functional biology space, has installed its innovative IsoLight single cell cytokine detection system at the Karolinska Institute in Sweden, as part of its expansion into Europe. In addition, IsoPlexis launched its first European office in the UK. This launch marks a significant milestone for IsoPlexis as they seek to advance both single-cell biology and precision medicine in Europe. Dr. Petter Brodin, Associate Professor of Immunology at the Karolinska Institute and Director of SciLifeLab Mass Cytometry Facility in Stockholm, stated, "We are excited to use the IsoLight to perform detailed functional analyses of immune cells sampled from newborn children during their first months and years of life. The ability of the IsoLight to provide detailed analyses from very few cells is key, given that we are limited to small sample quantities of blood."
IsoPlexis Receives $4 Million National Cancer Institute Grant for Commercialization of IsoLight for CAR-T Functional Quality Profiling, 2019 IsoPlexis, a company focused on advancing single-cell functional biomarkers to address critical challenges in oncology & beyond, today announced that it has received $4 million in grant funding from the National Cancer Institute's Small Business Innovation Research (NCI SBIR) Development Center as a part of the commercialization of the IsoLight system for use in CAR-T therapy product evaluation, quality check pre-infusion, and correlative studies. "This new funding demonstrates our leadership in and commitment to advancing the future of next generation CAR-T and other engineered T-cell therapies in blood cancers, solid tumor, and beyond" said Sean Mackay, IsoPlexis Chief Executive Officer and Co-Founder. "We appreciate the continued support of the National Cancer Institute and are excited to be in a position to accelerate the progress in this already fast-moving field."
IsoPlexis Completes $25 Million Series C Financing, 2019 IsoPlexis announced today that it had raised $25 million in Series C funding. The round was led by Northpond Ventures and included new strategic investment along with current investors Spring Mountain Capital, Ironwood Capital, North Sound Capital, and Connecticut Innovations. "We are pleased to lead the financing of IsoPlexis, an emerging leader in single cell analysis, which is catalyzing research in immunotherapy as well as a number of other high value applications," said Chris MacGriff of Northpond Ventures. In continuing its path forward, IsoPlexis continues to utilize its internal application engine and its partnerships with university professors and co-founders to build innovative single-cell products addressing high need disease areas. Additionally, IsoPlexis will expand its global operational, manufacturing, and commercial team across US, Europe and Asia, to add to the 105 employees IsoPlexis has currently.
IsoPlexis’ New IsoLight Instrument Receives the Red Dot Design Award for Highest Design Quality, 2018 The IsoLight sample-to-answer instrument receives the Red Dot Design Award for high design quality and focus on the user experience within the life sciences instrumentation category. The IsoLight's integrated design combines precision imaging and fluidics with a user-friendly software interface to create a uniquely easy to use single-cell system.
IsoPlexis Recognized with the Pharma Tech Outlook Cover Story as Top 10 Analytics Solution Provider in 2018, 2018 The award focuses on IsoPlexis' IsoSpeak software suite's ability to clarify results, reports, and associations from large, complex patient data sets, thereby delivering leading biopharma and clinical researchers better data by which to determine effective cancer immunotherapies.
Clinical Data Highlighting Single-Cell Polyfunctionality as a Potential Predictor of Patient Response to CAR-T Cell Therapy Published in Blood, 2018 The clinical data demonstrates a significant association between the functionality of anti-CD19 CAR-T cell product before treatment, as defined by IsoPlexis' Polyfunctional Strength Index (PSI), and the objective response in patients with non-Hodgkin lymphoma. The results highlight the potential to predict whether cancer patients will respond to CAR-T cell therapy before treatment, as well as to improve both pre-infusion product potency testing and guide cell product optimization. These findings have been published in Blood and are the result of a collaboration between IsoPlexis and Kite, a Gilead Company. Researchers used the IsoCode, IsoPlexis' single-cell precision engineering platform, to analyze CAR-T cell therapy products from 20 patients with non-Hodgkin lymphoma. Using IsoCode, researchers captured data to determine the PSI of each product. This PSI metric was associated with complete or partial patient response to the anti-CD19 CAR-T cell product. Other pre-infusion metrics tested in this study were not predictive.
IsoPlexis Announces Research Collaboration with Nektar Therapeutics, 2018 The collaboration is focused on further defining the functional impact of NKTR-214 in the clinic, at the single-cell level, with the goal of revealing both mechanism and potential immune correlates with outcome. Recently, preclinical data captured by IsoPlexis' IsoCode Chip in a study led by UCLA (AACR 2018) provided evidence that Nektar's cytokine agonist NKTR-214 can significantly boost the activation of critical T cell subsets, termed polyfunctional T cells, in combination with adoptive cell transfer (ACT) therapies.
IsoPlexis Places IsoLight Single-Cell Proteomic Detection Instrument at Fred Hutchinson Cancer Research Center, 2018 The sample-to-answer IsoLight benchtop system analyzes IsoPlexis' IsoCode chip to provide clinical and translational researchers a powerful, yet straightforward solution for establishing immune response functional correlates with outcome in key therapeutic areas like CAR-T and other cellular immunotherapies. The IsoCode Chip was recognized as The Scientist's and Fierce Life Science's #1 innovation of 2017 for its ability to provide both single-cell sensitivity and highly multiplexed and quantitative functional ELISA detection together for the first time.
IsoPlexis Announces Expansion into Asia Pacific, 2018 IsoPlexis announced today an exclusive agreement with Tekon Biotech, a leading instrumentation distributor, to distribute IsoPlexis' products in China. Tekon Biotech's first conference featuring IsoPlexis's systems will be held at Purple Mountain Hotel, Pudong, on September 20th, 2018 in Shanghai. "We are very excited to partner with Tekon Biotech, a world class distributor of life science systems and technology in China," said IsoPlexis Chief Executive Officer, Sean Mackay. "We see significant demand for our unique single-cell platform from leading Chinese pharmaceutical companies, research laboratories, and academic institutions. We are confident this partnership will help accelerate research in the fast emerging CAR-T therapy area in China, as we continue to extend our single-cell leadership into new markets."
Early Access to IsoPlexis’ Single Cell Analytics Platform Enhances Cell Therapy Program at World-renowned Research and Treatment Center, 2018 IsoPlexis, the leading developer of single-cell analytics solutions which enables complete immune cell profiling, has placed its ground-breaking IsoLight platform at City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases. IsoPlexis provides early access to its innovative platform to leading biopharmaceutical companies, researchers, and trial centers to generate proof of concept data and to solve immediate challenges in the fast moving immune-oncology field and beyond.
UCLA and Caltech Study Uses Technology Being Commercialized by IsoPlexis To Characterize Cancer Cells Resistant to Targeted Treatments, 2017 Research using novel single-cell detection technology being commercialized by IsoPlexis, called the Iso-Omix Chip, was highlighted in the Proceedings of the National Academy of Sciences. "Our single-cell proteomics technology allowed us to profile signaling pathways in melanoma cells that were both suppressed and activated via drugging. This, in turn, revealed how the cancer cells adapted and developed resistance to targeted treatments," said Dr. James Heath, a co-author of the UCLA paper and the Elizabeth W. Gilloon Professor of Chemistry at Caltech.
IsoPlexis Receives $5.6 Million in NIH Funding To Develop Next-Generation Single-Cell Assay Products, Technologies and Applications, 2017 “We’re excited to use this NIH grant support to advance our research and development in areas of solid tumor immunotherapies, bone marrow disease, autoimmune diseases and infectious diseases,” said Sean Mackay, IsoPlexis CEO and Co-Founder. “By expanding the application of our single-cell detection technologies, we aim to enable clinical researchers to better target their personalized treatments, at the single-cell level, and improve outcomes for high-need patients.”
IsoPlexis Receives $1.8M National Cancer Institute Grant To Develop Automated Platform To Assess CAR-T Product Potency and Toxicity and Predict Patient Response, 2017 "This new grant demonstrates the commitment to advancing CAR-T through investments, not only in the area of therapeutic discovery, but also in next-generation engineering technology," said Sean Mackay, IsoPlexis Chief Executive Officer and Co-Founder. "We're excited to be in a position to further enable this fast-growing field to better characterize and understand these complex therapies, and improve treatments for high-need patients."
IsoPlexis Raises $13.5 Million in Series B Financing, 2017 The Series B financing round was led by Spring Mountain Capital, with participation by Connecticut Innovations, North Sound Ventures, and Ironwood Capital. "IsoPlexis' collaboration data and product development has continued to demonstrate both the need for the IsoPlexis technology and the potential to have a large impact on improving patient outcomes," said Gregory P. Ho, President of Spring Mountain Capital and IsoPlexis Board Director. "We are excited to continue our partnership with the IsoPlexis team to move the company forward."
IsoPlexis and Kite Pharma Report Clinical Biomarker Data at AACR, 2017 IsoPlexis collaboration offers breakthrough insights into detecting and predicting patient response to t-cell therapy. Data captured by IsoCode, IsoPlexis' single-cell precision engineering platform, detected a statistically significant association between the potency of CAR-T cell product prior to treatment and objective response of cancer patients post-treatment. The results highlight the potential to predict whether cancer patients will respond to CAR-T cell therapy prior to treatment, as well as to improve both pre-infusion potency testing and cell product design.
IsoPlexis Obtains Exclusive License to Breakthrough Single-Cell Metabolomics Analysis Technologies From Dr. James Heath’s Lab at Caltech, 2017 Dr. James Heath’s new inventions enable detection of multiple types of metabolite information from single cells, a capability that aligns well with the IsoCode technology, previously referred to as the SCBC (single-cell barcode chip) solution and the foundation of IsoPlexis’ technologies.
IsoPlexis Adds Infectious Disease Pioneer Dr. David Ho to its Scientific Advisory Board, 2017 Dr. Ho is a recognized pioneer in the infectious disease area. He has authored more than 400 publications, was named Time magazine's 1996 Man of the Year for his pioneering work in AIDS research and is the recipient of 12 honorary doctorates for his scientific contributions.
IsoPlexis Awarded NIH SBIR Grant to Develop Single-Cell Analysis Platform to Facilitate Cancer Immunotherapy, 2017 IsoPlexis was recently awarded a competitive Phase I Small Business Innovation Research (SBIR) grant from the National Cancer Institute of the National Institutes of Health to develop a multi-protein, single-cell analysis platform to facilitate personalized cancer immunotherapy response detection.
IsoPlexis Awarded NIH SBIR Grant to Develop Cellular Analysis Platform to Diagnose and Monitor Alzheimer’s, 2017 IsoPlexis was recently awarded a competitive Phase I Small Business Innovation Research (SBIR) grant from the National Institute on Aging of the National Institutes of Health to develop a system to analyze trafficking leukocytes' highly multiplexed proteomic responses in patients with Alzheimer's disease.
Journal for ImmunoTherapy of Cancer Highlights New Single Cell Bioinformatics Tools From IsoPlexis Used To Characterize Differences in CAR-T Products, 2017 IsoCode, IsoPlexis' single-cell precision platform, captured novel data from CAR-T products developed by Novartis Pharmaceuticals (Novartis), leading to IsoPlexis' development of new bioinformatics tools for visualizing high-dimensional, single-cell, proteomics data. Researchers from IsoPlexis and Novartis published the results from their collaboration in the November issue of the Journal for ImmunoTherapy of Cancer.
The Scientist Names IsoPlexis Technology The Top Innovation of 2017, 2017 IsoPlexis’ single-cell technology recognized as a detection system poised to revolutionize clinical research and advance scientific knowledge. "Being named The Scientist’s No. 1 innovation of 2017 is another validation of the IsoPlexis technology’s role in utilizing our immune system to fight cancer," said Rong Fan, Ph.D., IsoPlexis Co-Founder and Scientific Advisory Board Chair, and an Associate Professor of Biomedical Engineering at Yale University. "IsoPlexis’ technology is helping researchers capture and understand large quantities of highly precise data, which will lead to more potent immunotherapies for more patients."
IsoPlexis Wins 2017 Fierce Technology Innovation Award, 2017 IsoPlexis’ IsoCode Chip and IsoLight Platform recognized by publishers of FierceBiotech and FiercePharma as this year’s top technology innovation in the life sciences space. "It is an honor to receive this award from the publishers of FierceBiotech and FiercePharma," said Sean Mackay, IsoPlexis Chief Executive Officer and Co-Founder. "Clinical researchers at leading academic and biopharmaceutical labs are using IsoPlexis technology to better understand how to use the human immune system in the fight against cancer, and we're proud that our technology is helping to advance more personalized and more potent immunotherapies for patients that need them the most."
IsoPlexis Appoints Academic and Industry Experts to Inaugural Scientific Advisory Board, 2015 IsoPlexis today announced the formation of a scientific advisory board (SAB) to help guide the company’s strategic direction in novel areas of immunology and oncology.